Uncommon Heart Condition Link: When ARVC Mimics Cardiac Microvascular Disease
"Explore the rare connection between Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) and cardiac microvascular disease, uncovering potential risks and diagnostic challenges."
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is a heart condition marked by dangerous ventricular arrhythmias, an elevated risk of sudden cardiac death (SCD), and impaired right ventricular function. It's like a perfect storm in your heart, where electrical glitches meet structural changes, potentially leading to life-threatening events.
Microvascular disease occurs when the small blood vessels of the heart don't dilate properly, limiting blood flow. This can lead to chest pain and other symptoms, even when the main coronary arteries appear normal. It’s like having a hidden network of tiny blockages that starve your heart muscle of oxygen.
Normally, these conditions are seen as separate issues, but what happens when they occur together? This article explores a fascinating case study that suggests a possible link between ARVC and cardiac microvascular disease, raising important questions about diagnosis, risk assessment, and treatment strategies.
Prevalence and Clinical Impact
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a progressive inherited heart disease characterized by ventricular arrhythmias and sudden cardiac death, especially in young people. A 2025 review describes ARVC as a rare disease involving fibrofatty myocardial infiltration and a predisposition to ventricular arrhythmias, heart failure, and sudden cardiac death. A German medical review reports an estimated prevalence of 1 in 2,000 to 1 in 5,000 and describes progressive replacement of heart muscle by fatty and connective tissue.
Diagnostic Complexity
ARVC is characterized by right ventricular fibrofatty infiltration and a predominantly arrhythmic presentation, although biventricular involvement is now frequently recognized. Affected individuals typically present between the second and fourth decades of life with arrhythmias arising from the right ventricle. The literature also identifies pathogenic mutations in genes encoding cardiac desmosomes, while newer descriptions use the broader term arrhythmogenic cardiomyopathy because the disease may extend beyond the right ventricle.
A Heritable Right-Ventricular Disorder
ARVC, also known as arrhythmogenic right ventricular dysplasia, is described as a heritable heart-muscle disorder. Its predominant site of involvement is the right ventricle. This framing established ARVC as a distinct disorder of heart muscle rather than simply an isolated rhythm abnormality.
A Unique Case: ARVC Masquerading as Microvascular Disease
In 1999, a 59-year-old woman with a history of "crescendo" angina (increasingly frequent and severe chest pain) underwent evaluation. Her father had died at age 60 from a heart attack, adding to the concern. Initially, her physical examination seemed normal, and an electrocardiogram (ECG) showed a regular sinus rhythm with some minor T-wave abnormalities.
- Echocardiogram: Showed dilation and reduced ejection fraction in the right ventricle, but no issues in the left ventricle.
- 24-hour ECG (Holter monitor): Recorded two episodes of ST-segment depression, coinciding with chest pain.
- Treadmill stress test: Provoked chest pain during exercise, along with ST-segment depression on the ECG.
- Cardiac MRI: Confirmed fibro-fatty replacement of the myocardium (heart muscle) and right chamber enlargement, along with thinning and aneurysmal dilatation of the right ventricular wall.
- Coronary angiography: Showed normal coronary arteries, but an invasive coronary flow reserve study revealed increased coronary flow resistance and impaired response to certain medications.
- Endomyocardial biopsies: Revealed fibro-fatty tissue replacement in both the right and left ventricles.
An Unresolved Prognostic Question
Recent review literature has examined coronary microvascular dysfunction (CMD) in cardiomyopathies. For ARVC specifically, the available review reports that data on CMD's possible prognostic implications remain lacking. This means that a possible microvascular abnormality should not yet be treated as an established prognostic marker in ARVC.
Evidence and Its Limits
In a small, well-characterized cohort of patients with nonfailing ARVC, investigators found significantly reduced hyperemic myocardial blood flow (MBF) and increased coronary vascular resistance (CVR). A separate H215O-PET report likewise found reduced hyperemic MBF associated with increased CVR in ARVC patients. However, both reports state that further studies are needed, and a later analysis emphasizes that its results must be interpreted in light of methodological limitations.
Fibrosis and Immune Context
ARVC is described as a life-threatening inherited myocardial disease and a common cause of malignant ventricular arrhythmias or sudden cardiac death in young adults and athletes. Its characteristic pathology is progressive fibrofatty replacement of functional myocardium, predominantly in the right ventricle. Research has also examined dominant myocardial fibrosis together with the immune microenvironment as part of ARVC pathogenesis.
What Does This Mean for You?
This case highlights the complex nature of heart disease and the importance of thorough evaluation. If you experience chest pain, especially with other symptoms like palpitations or shortness of breath, it’s essential to consult a cardiologist. While the link between ARVC and microvascular disease is rare, recognizing the possibility can lead to more accurate diagnoses and tailored treatment plans.
Consensus-Guided Care
The 2019 HRS expert consensus statement provides clinicians with guidance on evaluating and managing arrhythmogenic cardiomyopathy. It includes clinically relevant information on genetics and disease mechanisms. The statement also uses contemporary evidence to address exercise in ARVC through focused clinical questions.
Mimics and Individual Risk
A 2025 JACC case report highlights the importance of considering mimics when ARVC is suspected, even when diagnostic criteria appear to support a definite diagnosis. A separate 2026 report states that exercise recommendations for athletes with arrhythmogenic cardiomyopathy are shifting toward an individualized and genotype-informed approach. It specifically describes athletes with ARVC as a group in whom continued high-intensity endurance exercise is considered to carry higher risks of disease progression and sudden cardiac death.